185 related articles for article (PubMed ID: 28654024)
1. Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors.
Phan AT
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):10-14. PubMed ID: 28654024
[No Abstract] [Full Text] [Related]
2. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
Khagi S; Saif MW
JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
[TBL] [Abstract][Full Text] [Related]
3. Refining the management of patients with gastroenteropancreatic neuroendocrine tumors.
Iyer R
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):3-10. PubMed ID: 28654023
[No Abstract] [Full Text] [Related]
4. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
Khagi S; Saif MW
JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
[TBL] [Abstract][Full Text] [Related]
5. Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):10-1. PubMed ID: 27168105
[No Abstract] [Full Text] [Related]
6. [Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system].
Auernhammer CJ; Spitzweg C; Böck S; Knösel T; Bartenstein P
Dtsch Med Wochenschr; 2019 Oct; 144(20):1390-1395. PubMed ID: 31594011
[TBL] [Abstract][Full Text] [Related]
7. New Radiopharmaceutical Approved to Treat Rare Digestive Tract Cancer.
Aschenbrenner DS
Am J Nurs; 2018 May; 118(5):22-23. PubMed ID: 29698274
[No Abstract] [Full Text] [Related]
8. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.
Chandrasekharan C
Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362
[TBL] [Abstract][Full Text] [Related]
9. The potential role of targeted therapies in the management of neuroendocrine tumours.
Verset G; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Verslype C; Van Laethem JL
Acta Gastroenterol Belg; 2009; 72(1):59-62. PubMed ID: 19402374
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
11. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Modlin I
Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
16. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.
Amair-Pinedo F; Matos I; Saurí T; Hernando J; Capdevila J
Target Oncol; 2017 Dec; 12(6):757-774. PubMed ID: 29143176
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
Boucher JE; Sommers R
Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
[TBL] [Abstract][Full Text] [Related]
18. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
19. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Strosberg J; Goldman J; Costa F; Pavel M
Front Horm Res; 2015; 44():239-47. PubMed ID: 26303716
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
Iyer R; Phan AT; Boudreaux JP
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):1-24. PubMed ID: 28654022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]